TNFRSF4 and neoplasm: In this study, we developed an in situ vaccine combining radiotherapy, CpG and OX40 agonistic antibody to induce systemic tumor-specific immune responses that exert suppressive effect to both local (treated) and abscopal (untreated) tumors.